#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Dermatitis atopic+1

Recruiting

Investigational

Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis

Investigational

France

Participants:0–17 years
Substances:Lebrikizumab

Contact Research Centre

Eczema nummular

Recruiting

Registered drug

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Lebrikizumab

Contact Research Centre

Vitiligo+2

Recruiting

InvestigationalNo placebo

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Povorcitinib

Contact Research Centre

Neurodermatitis

Recruiting

Investigational

ICP-332 for Adults with Prurigo Nodularis

Investigational

France

Participants:18–64 years · 65+ years

Contact Research Centre

Alopecia areata

Recruiting

Investigational

Long-term safety and effectiveness study of ritlecitinib in children with severe alopecia areata who completed previous trials B7981027 or B7981031

Investigational

France

Participants:0–17 years

Contact Research Centre

Dermatitis atopic

Not recruiting

Investigational

Study of Ruxolitinib Cream for Children and Adolescents Ages 6-17 with Moderate Atopic Dermatitis Who Did Not Respond Well to Standard Treatments

Investigational

France

Participants:0–17 years
Substances:Ruxolitinib

Contact Research Centre

Psoriasis

Not recruiting

Registered drug

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Apremilast

Contact Research Centre

Neurodermatitis

Not recruiting

Investigational

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational

France

Participants:18–64 years · 65+ years
Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide

Contact Research Centre

Dermatitis atopic

Not recruiting

Registered drug

Study of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug

France

Participants:0–17 years
Substances:Baricitinib

Contact Research Centre

Dermatitis atopic

Not recruiting

Registered drug

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab

Contact Research Centre

Dermatitis atopic

Not recruiting

Registered drug

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab

Contact Research Centre

Dermatitis atopic

Not recruiting

Registered drugNo placebo

Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.